Kisspeptin for Libido & Fertility: What the Research Shows

Kisspeptin is not a supplement on a wellness shelf or a peptide sold at the gym. It is a hypothalamic neuropeptide encoded by the KISS1 gene that functions as the master regulator of the reproductive axis — controlling the pulsatile release of gonadotropin-releasing hormone (GnRH) and, downstream, the entire hormonal cascade governing fertility and sexual function^[1]. Since 2017, a team at Imperial College London led by Professor Waljit Dhillo has published a series of human studies — including brain-imaging experiments and randomised controlled trials — showing that exogenous kisspeptin modulates how the brain processes sexual stimuli, and that it can improve measures of desire in people with hypoactive sexual desire disorder (HSDD). Separately, kisspeptin-54 has been evaluated as a safer alternative to hCG for triggering oocyte maturation in IVF patients at high risk of ovarian hyperstimulation syndrome (OHSS). This article covers what that research actually shows, explains what kisspeptin is at a biological level, and is honest about something that wellness marketing routinely obscures: kisspeptin is a research-stage compound, not an approved or widely available treatment for libido or fertility. For the broader peptide-research landscape, see our peptides hub.

What Is Kisspeptin? The KISS1 Gene and the GnRH Axis

Kisspeptin is a family of neuropeptides — the most studied forms being kisspeptin-54, kisspeptin-14, kisspeptin-13, and kisspeptin-10, named by amino-acid length — all derived from a precursor protein encoded by the KISS1 gene. They act on a single receptor, KISS1R (also known as GPR54), expressed densely on GnRH-secreting neurons in the hypothalamic arcuate nucleus and anteroventral periventricular nucleus. When kisspeptin binds KISS1R on these GnRH neurons, it triggers pulsatile GnRH release, which drives pituitary secretion of luteinising hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulate gonadal function^[1]. This makes kisspeptin the "gatekeeper" of puberty onset and adult reproductive cycling in humans.

The clinical importance of the KISS1/KISS1R axis became clear when loss-of-function mutations in KISS1R were found to cause congenital hypogonadotropic hypogonadism — a condition in which puberty fails entirely because the GnRH pulse generator never activates^[7]. That discovery established kisspeptin as an essential human reproductive signal and motivated researchers to ask whether exogenous kisspeptin could restore or modulate reproductive function in conditions where the axis is disrupted or suboptimally active — including fertility disorders and states of low sexual desire.

Kisspeptin and Sexual Brain Processing: Human fMRI Evidence

The most cited evidence on kisspeptin and sexual brain function comes from a 2017 study in The Journal of Clinical Investigation by Comninos and colleagues^[1]. The study gave kisspeptin-54 or saline placebo intravenously to healthy men and then measured brain activation using functional MRI (fMRI) while participants viewed sexual, rewarding, and aversive imagery. Kisspeptin significantly enhanced activation in brain regions associated with sexual processing — including the anterior cingulate cortex and interconnected limbic areas — while simultaneously attenuating activation of regions involved in aversive emotional states. The authors concluded that kisspeptin modulates the neural circuitry of both sexual motivation and emotional salience in humans, a central action that goes beyond simple stimulation of the pituitary–gonadal axis.

A 2018 follow-up study from the same group, published in JCI Insight^[2], extended those findings using resting-state fMRI — measuring how kisspeptin altered intrinsic functional connectivity across brain networks rather than task-evoked responses. Kisspeptin-54 modulated connectivity within circuits linking the hypothalamus with limbic and prefrontal regions implicated in emotional and sexual function. Together, the 2017 and 2018 studies established that kisspeptin acts not only on the pituitary–gonadal axis but directly on higher brain centres involved in desire and motivation — a neurological footprint that distinguishes it from simpler hormonal interventions.

Randomised Trial Evidence in People With Hypoactive Sexual Desire Disorder

Moving from healthy volunteers to people with diagnosed sexual dysfunction, the Imperial College group published two double-blind, placebo-controlled randomised clinical trials in JAMA Network Open examining kisspeptin's effects in people with hypoactive sexual desire disorder (HSDD) — a clinical diagnosis requiring persistent, distressing low desire not explained by another medical, psychiatric, or relational cause. The first trial (Thurston et al., 2022)^[3] enrolled women with HSDD and administered intravenous kisspeptin-54 versus saline. Kisspeptin significantly increased neural responses to sexual stimuli on fMRI and improved self-reported sexual desire ratings compared to placebo — the first placebo-controlled human trial to demonstrate measurable effects of kisspeptin on subjective desire in a clinical HSDD population.

The companion trial (Mills et al., 2023)^[4] enrolled men with HSDD and found that intravenous kisspeptin-54 enhanced sexual brain processing on fMRI and increased objective penile tumescence responses to sexual stimuli compared to placebo. Both trials used intravenous kisspeptin-54 — not an oral supplement or a self-administered peptide injection — meaning the delivery method itself is far from a consumer-ready format. Neither trial assessed long-term outcomes, repeat dosing, or active pharmacological comparators. These are early-phase, proof-of-concept trials establishing that the effect exists, not definitive evidence of a treatment ready for routine clinical use.

Kisspeptin as a Fertility Treatment: The IVF-Trigger Research

The most clinically advanced application of kisspeptin is as an alternative to human chorionic gonadotropin (hCG) for triggering final oocyte maturation in IVF cycles. Standard IVF uses an hCG injection to mimic the LH surge and trigger oocyte release — but in women with polycystic ovary syndrome (PCOS) or other conditions that cause hyperresponsiveness to stimulation, hCG carries a meaningful risk of ovarian hyperstimulation syndrome (OHSS), a potentially serious complication. Because kisspeptin stimulates an endogenous LH surge rather than substituting directly for LH or hCG, it has been hypothesised to carry a more favourable OHSS risk profile.

A 2015 trial by Abbara and colleagues published in The Journal of Clinical Endocrinology & Metabolism^[5] demonstrated that kisspeptin-54 successfully triggered oocyte maturation in women at high risk of OHSS, with no cases of severe OHSS in the kisspeptin group. A 2017 follow-up in Human Reproduction^[6] found that a second dose of kisspeptin-54 further improved oocyte maturation rates in this population. Broader investigational work on kisspeptin receptor agonists^[7] has continued to explore therapeutic potential across female reproductive disorders. Despite this promising evidence, kisspeptin is not currently the standard of care for IVF triggering — hCG and GnRH agonist triggers remain standard in most clinics worldwide, and kisspeptin's IVF role, while scientifically compelling, remains investigational.

Honest Status: Research-Stage, Not a Consumer Product

Why Kisspeptin Is Scientifically Distinctive

What makes kisspeptin genuinely interesting — and distinguishes it from the typical grey-market research peptide — is its central position in human reproductive neurobiology. Most peptides promoted in wellness contexts are growth-hormone secretagogues, tissue-repair agents, or melanocortin-receptor agonists like PT-141/bremelanotide. Kisspeptin is different: it is the body's own endogenous "on switch" for the reproductive axis. Its documented effects on desire and fertility are not pharmacological workarounds — they arise because kisspeptin is literally the physiological signal that activates GnRH, LH, FSH, and the gonadal hormones downstream^[1].

The brain-imaging evidence adds a second dimension: kisspeptin's effects on desire may not operate exclusively through testosterone or estrogen but through direct central actions on limbic circuits governing motivation and emotional processing^[1][2]. That is a mechanistically distinct pathway from any approved sexual-health drug on the market. Whether that translates into a clinically meaningful, safe, and durable treatment for low desire remains an open question — one being rigorously pursued in academic settings, not yet answered. For people interested in the evidence landscape of reproductive peptide research more broadly, our peptide research hub covers the full range of compounds under investigation.